In recent years, the global radiopharmaceutical market has been booming rapidly. With its unique advantage of theranostics, Nuclear Medicine has gradually become a new focus in the medical field. In 2024, the transaction amount of radiopharmaceutical-related mergers and acquisitions agreements have exceeded 10 billion US dollars. Meanwhile with the Chinese government's attention and support for the field of nuclear medicine, especially after the introduction and implementation of policies and guidelines such as the "Medium- and Long-Term Development Plan for Medical Isotopes (2021-2035)", China’s nuclear medicine market has ushered in rapid development. According to Frost & Sullivan data, China's radiopharmaceutical market for imaging diagnosis and treatment is expected to grow at a compound annual growth rate of 22.7% from 2025 to 2030, and the market size is expected to climb to 26 billion yuan by 2030. In view of this, the Targeted Radiopharmaceuticals Innovation Forum 2025 (TRPI2025) will gather leaders and scientists with the aim to facilitate the communication and partnership on the Frontier and Progress of Next-generation Targeted Radiopharmaceuticals, Early Discovery, Non-Clinical Development and Clinical Translation of Novel Diagnostic and Therapeutic Radiopharmaceuticals, Theranostics and Precision Medicine, Targeted Alpha Therapy and Emerging Medical Isotopes, Novel Targets and RDC, Dual-Targeted Radiopharmaceuticals and Combination Therapy, CMC Development, Manufacturing and Quality Control. Currently we are receiving the presentation abstracts for TRPI2025. If you'd be interested in speaking, please contact Wei Zhang at wzhang@deliver-consulting.com.